A multicenter, randomized, controlled trial of Qingyu Powder in the treatment of mild to moderate active ulcerative colitis

Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1) accord with the diagnostic standard of western medicine for ulcerative colitis;
•2) the selected patients were mild to moderate ulcerative colitis (total Mayo score = 310);
•3) Aged 18-65 years old;
•4) agree to participate in this study and sign the informed letter at the same time.

•(1) infectious colitis such as bacillary dysentery, amoebic dysentery, chronic schistosomiasis, intestinal tuberculosis, Crohn's disease and ischemic intestine;
•Patients with inflammatory and radiation enteritis;
•(2) there are serious complications such as local stenosis, intestinal obstruction, intestinal perforation, toxic colonic dilatation, massive hemorrhage, colon cancer and rectal cancer;
•(3) patients with other primary and secondary infectious diseases, such as cholecystitis, pneumonia, etc.;
•(4) patients with serious diseases of cardiovascular, hepatobiliary, lung, kidney and blood system;
•(5) Women during pregnancy and lactation;
•(6) patients with disabilities prescribed by law (blindness, deafness, mute, mental retardation, physical disability);
•(7) patients with severe ulcerative colitis (Mayo=11~12 score); or patients with complications.

发起方

Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine